{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:52:23Z","timestamp":1793371943537,"version":"4.5.0"},"reference-count":160,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bioorg.2025.108985","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T09:35:26Z","timestamp":1757756126000},"page":"108985","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Targeted protein degradation in pancreatic cancer: advances and challenges of PROTAC-based therapeutics"],"prefix":"10.1016","volume":"165","author":[{"given":"Mingyao","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jilong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhou","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2023","key":"10.1016\/j.bioorg.2025.108985_bb0005","first-page":"17","article-title":"Cancer statistics","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2025.108985_bb0010","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"issue":"2011","key":"10.1016\/j.bioorg.2025.108985_bb0015","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"1817","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2025.108985_bb0020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev-pharmtox-010715-103440","article-title":"Drugging undruggable molecular cancer targets","volume":"56","author":"Lazo","year":"2016","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.bioorg.2025.108985_bb0025","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioorg.2025.108985_bb0030","first-page":"511","article-title":"Research progress of PROTAC-degraded CDKs in the treatment of breast cancer","volume":"17","author":"Zhao","year":"2025","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"10.1016\/j.bioorg.2025.108985_bb0035","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-targeting chimeras as therapeutics and tools for biological discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2025.108985_bb0040","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nchembio.1858","article-title":"Catalytic in vivo protein knockdown by small-molecule PROTACs","volume":"11","author":"Bondeson","year":"2015","journal-title":"Nat. Chem. Biol."},{"issue":"31","key":"10.1016\/j.bioorg.2025.108985_bb0045","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202507702","article-title":"Unconventional PROTACs for targeted protein degradation in cancer therapy","volume":"64","author":"Zhang","year":"2025","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.bioorg.2025.108985_bb0050","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/d41573-021-00052-4","article-title":"Targeted protein degraders crowd into the clinic","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2025.108985_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118297","article-title":"Advances in DNA-based proteolysis-targeting chimeras technology: novel strategies for targeting previously undruggable proteins in cancer therapy","volume":"129","author":"Hou","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108985_bb0060","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41698-025-00931-8","article-title":"Targeting CDKs in cancer therapy: advances in PROTACs and molecular glues","volume":"9","author":"Marei","year":"2025","journal-title":"NPJ Precis. Oncol."},{"issue":"2025","key":"10.1016\/j.bioorg.2025.108985_bb0065","article-title":"Advancing design strategy of PROTACs for cancer therapy","volume":"6","author":"Luo","year":"2020","journal-title":"MedComm"},{"key":"10.1016\/j.bioorg.2025.108985_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17111871","article-title":"Targeting the undruggable: recent progress in PROTAC-induced transcription factor degradation","volume":"17","author":"Jung","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2025.108985_bb0075","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1152\/physrev.00027.2001","article-title":"The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction","volume":"82","author":"Glickman","year":"2002","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.bioorg.2025.108985_bb0080","first-page":"933","article-title":"Chemically induced cellular proteolysis: an emerging therapeutic strategy for undruggable targets","volume":"41","author":"Moon","year":"2018","journal-title":"Mol. Cells"},{"key":"10.1016\/j.bioorg.2025.108985_bb0085","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/med.21992","article-title":"The new direction of drug development: degradation of undruggable targets through targeting chimera technology","volume":"44","author":"Liang","year":"2024","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2025.108985_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104032","article-title":"The impact of E3 ligase choice on PROTAC effectiveness in protein kinase degradation","volume":"29","author":"Sobierajski","year":"2024","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2025.108985_bb0095","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41589-019-0294-6","article-title":"BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design","volume":"15","author":"Farnaby","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.108985_bb0100","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1021\/acschembio.0c00266","article-title":"Structural insights into PROTAC-mediated degradation of Bcl-xL","volume":"15","author":"Chung","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.108985_bb0105","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/anie.201914396","article-title":"Structure-based design of a macrocyclic PROTAC","volume":"59","author":"Testa","year":"2020","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.bioorg.2025.108985_bb0110","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1021\/acschembio.9b00092","article-title":"SPR-measured dissociation kinetics of PROTAC ternary complexes influence target degradation rate","volume":"14","author":"Roy","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.108985_bb0115","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.molcel.2017.06.004","article-title":"BET bromodomain proteins function as master transcription elongation factors independent of CDK9 recruitment","volume":"67","author":"Winter","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bioorg.2025.108985_bb0120","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1021\/jacs.0c10008","article-title":"Development of antibody-based PROTACs for the degradation of the cell-surface immune checkpoint protein PD-L1","volume":"143","author":"Cotton","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bioorg.2025.108985_bb0125","doi-asserted-by":"crossref","first-page":"E7285","DOI":"10.1073\/pnas.1803662115","article-title":"Delineating the role of cooperativity in the design of potent PROTACs for BTK","volume":"115","author":"Zorba","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioorg.2025.108985_bb0130","doi-asserted-by":"crossref","first-page":"eado6492","DOI":"10.1126\/sciadv.ado6492","article-title":"Mechanism of degrader-targeted protein ubiquitinability","volume":"10","author":"Crowe","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bioorg.2025.108985_bb0135","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/nchembio.2209","article-title":"Design and characterization of bivalent BET inhibitors","volume":"12","author":"Tanaka","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.108985_bb0140","doi-asserted-by":"crossref","first-page":"16078","DOI":"10.1038\/ncomms16078","article-title":"Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy","volume":"8","author":"Inoue-Yamauchi","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2025.108985_bb0145","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/13543784.2025.2511175","article-title":"Treating KRAS G12C lung cancer: therapeutic potential of investigation drugs in early clinical study","volume":"34","author":"Wilson","year":"2025","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bioorg.2025.108985_bb0150","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1756-8722-6-59","article-title":"Ibrutinib and novel BTK inhibitors in clinical development","volume":"6","author":"Akinleye","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2025.108985_bb0155","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"Drug development. Phthalimide conjugation as a strategy for in vivo target protein degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2025.108985_bb0160","doi-asserted-by":"crossref","first-page":"11280","DOI":"10.1021\/acs.jmedchem.9b01530","article-title":"Structure-based discovery of SD-36 as a potent, selective, and efficacious PROTAC degrader of STAT3 protein","volume":"62","author":"Zhou","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108985_bb0165","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/anie.201507634","article-title":"Modular PROTAC design for the degradation of oncogenic BCR-ABL","volume":"55","author":"Lai","year":"2016","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.bioorg.2025.108985_bb0170","doi-asserted-by":"crossref","first-page":"6890","DOI":"10.1039\/D0CC02201B","article-title":"Scaffold hopping enables direct access to more potent PROTACs with in vivo activity","volume":"56","author":"Burslem","year":"2020","journal-title":"Chem. Commun. (Camb.)"},{"key":"10.1016\/j.bioorg.2025.108985_bb0175","doi-asserted-by":"crossref","first-page":"8567","DOI":"10.1021\/acs.jmedchem.0c00967","article-title":"Global PROTAC toolbox for degrading BCR-ABL overcomes drug-resistant mutants and adverse effects","volume":"63","author":"Yang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108985_bb0180","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cbpa.2020.12.003","article-title":"The rise of covalent proteolysis targeting chimeras","volume":"62","author":"Gabizon","year":"2021","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.108985_bb0185","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1039\/C9CC08238G","article-title":"Protein degradation through covalent inhibitor-based PROTACs","volume":"56","author":"Xue","year":"2020","journal-title":"Chem. Commun. (Camb.)"},{"key":"10.1016\/j.bioorg.2025.108985_bb0190","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1021\/acs.biochem.8b00391","article-title":"Targeting the C481S ibrutinib-resistance mutation in Bruton\u2019s tyrosine kinase using PROTAC-mediated degradation","volume":"57","author":"Buhimschi","year":"2018","journal-title":"Biochemistry"},{"key":"10.1016\/j.bioorg.2025.108985_bb0195","doi-asserted-by":"crossref","first-page":"7839","DOI":"10.1021\/acs.jmedchem.1c00649","article-title":"Rational design and synthesis of novel dual PROTACs for simultaneous degradation of EGFR and PARP","volume":"64","author":"Zheng","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108985_bb0200","doi-asserted-by":"crossref","first-page":"17691","DOI":"10.1039\/D4SC03555K","article-title":"Dual-ligand PROTACS mediate superior target protein degradation in vitro and therapeutic efficacy in vivo","volume":"15","author":"Chen","year":"2024","journal-title":"Chem. Sci."},{"key":"10.1016\/j.bioorg.2025.108985_bb0205","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1002\/anie.202012330","article-title":"RNA-PROTACs: degraders of RNA-Binding Proteins","volume":"60","author":"Ghidini","year":"2021","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.bioorg.2025.108985_bb0210","first-page":"648","article-title":"Targeted degradation of transcription factors by TRAFTACs: TRAnscription factor TArgeting chimeras, cell","volume":"28","author":"Samarasinghe","year":"2021","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.108985_bb0215","article-title":"Destruction of DNA-binding proteins by programmable oligonucleotide PROTAC (O\u2019PROTAC): effective targeting of LEF1 and ERG","volume":"8","author":"Shao","year":"2021","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.bioorg.2025.108985_bb0220","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.omtn.2022.09.008","article-title":"Development of a novel PROTAC using the nucleic acid aptamer as a targeting ligand for tumor selective degradation of nucleolin","volume":"30","author":"Zhang","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.bioorg.2025.108985_bb0225","doi-asserted-by":"crossref","first-page":"12816","DOI":"10.1039\/D1CC05025G","article-title":"G4-PROTAC: targeted degradation of a G-quadruplex binding protein","volume":"57","author":"Patil","year":"2021","journal-title":"Chem. Commun. (Camb.)"},{"key":"10.1016\/j.bioorg.2025.108985_bb0230","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.omtn.2020.05.025","article-title":"Aptamers against live targets: is in vivo SELEX finally coming to the edge?","volume":"21","author":"Sola","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.bioorg.2025.108985_bb0235","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2018.04.007","article-title":"Aptamer chemistry","volume":"134","author":"Rothlisberger","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioorg.2025.108985_bb0240","doi-asserted-by":"crossref","first-page":"9500","DOI":"10.1021\/acsami.0c05750","article-title":"Recent progress in aptamer discoveries and modifications for therapeutic applications","volume":"13","author":"Ni","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.bioorg.2025.108985_bb0245","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17010040","article-title":"Peptide aptamer-paclitaxel conjugates for tumor targeted therapy","volume":"17","author":"Shen","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioorg.2025.108985_bb0250","doi-asserted-by":"crossref","first-page":"10141","DOI":"10.7150\/thno.46985","article-title":"The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination","volume":"10","author":"Jin","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.bioorg.2025.108985_bb0255","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s13046-022-02483-2","article-title":"Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression","volume":"41","author":"Wang","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108985_bb0260","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.7150\/thno.41677","article-title":"A cell-permeable peptide-based PROTAC against the oncoprotein CREPT proficiently inhibits pancreatic cancer","volume":"10","author":"Ma","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.bioorg.2025.108985_bb0265","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1021\/acs.jmedchem.3c01493","article-title":"Degradation of polo-like kinase 1 by the novel poly-arginine N-Degron pathway PROTAC regulates tumor growth in nonsmall cell lung cancer","volume":"67","author":"Gunasekaran","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108985_bb0270","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.tibs.2017.09.002","article-title":"The ubiquitin code in the ubiquitin-proteasome system and autophagy","volume":"42","author":"Kwon","year":"2017","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bioorg.2025.108985_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109719","article-title":"Drosophila Uev1a is dually required for ben-dependent DNA-damage response and fly mobility","volume":"74","author":"Bai","year":"2020","journal-title":"Cell. Signal."},{"key":"10.1016\/j.bioorg.2025.108985_bb0280","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202306013","article-title":"USP8 prevents aberrant NF-kappaB and Nrf2 activation by counteracting ubiquitin signals from endosomes","volume":"223","author":"Endo","year":"2024","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bioorg.2025.108985_bb0285","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1038\/onc.2010.190","article-title":"Emerging role of Lys-63 ubiquitination in protein kinase and phosphatase activation and cancer development","volume":"29","author":"Yang","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2025.108985_bb0290","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.tcb.2011.08.008","article-title":"K11-linked ubiquitin chains as novel regulators of cell division","volume":"21","author":"Wickliffe","year":"2011","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.bioorg.2025.108985_bb0295","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1111\/febs.16425","article-title":"M1-linked ubiquitination facilitates NF-kappaB activation and survival during sterile inflammation","volume":"289","author":"Aalto","year":"2022","journal-title":"FEBS J."},{"key":"10.1016\/j.bioorg.2025.108985_bb0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s11658-020-00245-6","article-title":"Beyond K48 and K63: non-canonical protein ubiquitination","volume":"26","author":"Tracz","year":"2021","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.bioorg.2025.108985_bb0305","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bbrc.2023.01.051","article-title":"Cereblon neo-substrate binding mimics the recognition of the cyclic imide degron","volume":"646","author":"Heim","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bioorg.2025.108985_bb0310","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","article-title":"Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4","volume":"22","author":"Lu","year":"2015","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.108985_bb0315","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejmech.2019.01.023","article-title":"A novel cereblon modulator for targeted protein degradation","volume":"166","author":"Kim","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108985_bb0320","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1021\/acsmedchemlett.2c00436","article-title":"Phenyl Dihydrouracil: An alternative cereblon binder for PROTAC design","volume":"14","author":"Jarusiewicz","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108985_bb0325","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1021\/acschembio.7b00969","article-title":"Translation termination factor GSPT1 is a phenotypically relevant off-target of heterobifunctional phthalimide degraders","volume":"13","author":"Ishoey","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.108985_bb0330","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.str.2017.04.009","article-title":"Crystal structure of the Cul2-Rbx1-EloBC-VHL ubiquitin ligase complex","volume":"25","author":"Cardote","year":"2017","journal-title":"Structure"},{"key":"10.1016\/j.bioorg.2025.108985_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217102","article-title":"Aptamer functionalized hypoxia-potentiating agent and hypoxia-inducible factor inhibitor combined with hypoxia-activated prodrug for enhanced tumor therapy","volume":"598","author":"Ma","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2025.108985_bb0340","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nrc2502","article-title":"The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer","volume":"8","author":"Kaelin","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2025.108985_bb0345","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1021\/ja209924v","article-title":"Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL\/HIF-1alpha interaction","volume":"134","author":"Buckley","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bioorg.2025.108985_bb0350","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1021\/acs.jmedchem.7b00675","volume":"61","author":"Soares","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108985_bb0355","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1021\/acs.jmedchem.3c02123","article-title":"Structure-guided design and optimization of covalent VHL-targeted sulfonyl fluoride PROTACs","volume":"67","author":"Shah","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108985_bb0360","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1016\/j.apsb.2024.04.007","article-title":"Characteristic roadmap of linker governs the rational design of PROTACs","volume":"14","author":"Dong","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2025.108985_bb0365","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41467-017-00954-1","article-title":"Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation","volume":"8","author":"Maniaci","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2025.108985_bb0370","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41467-018-08027-7","article-title":"Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase","volume":"10","author":"Smith","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2025.108985_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112451","article-title":"Optimal linker length for small molecule PROTACs that selectively target p38alpha and p38beta for degradation","volume":"201","author":"Donoghue","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108985_bb0380","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1021\/acs.jmedchem.3c00075","article-title":"Discovery of a potent, cooperative, and selective SOS1 PROTAC ZZ151 with in vivo antitumor efficacy in KRAS-mutant cancers","volume":"66","author":"Zhou","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108985_bb0385","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1021\/acs.jmedchem.8b01631","article-title":"Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer","volume":"62","author":"Han","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108985_bb0390","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1021\/acs.jcim.0c00589","article-title":"PRosettaC: Rosetta based modeling of PROTAC mediated ternary complexes","volume":"60","author":"Zaidman","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2025.108985_bb0395","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1021\/acs.jcim.1c01150","article-title":"Importance of three-body problems and protein-protein interactions in proteolysis-targeting chimera modeling: insights from molecular dynamics simulations","volume":"62","author":"Li","year":"2022","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2025.108985_bb0400","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1021\/acs.jcim.2c01287","article-title":"Fragment linker prediction using the deep encoder-decoder network for PROTACs drug design","volume":"63","author":"Kao","year":"2023","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2025.108985_bb0405","doi-asserted-by":"crossref","first-page":"5524","DOI":"10.1021\/acs.jmedchem.2c01864","article-title":"Catalytic degraders effectively address kinase site mutations in EML4-ALK oncogenic fusions","volume":"66","author":"Gao","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108985_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116520","article-title":"Application and challenges of nitrogen heterocycles in PROTAC linker","volume":"273","author":"Li","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108985_bb0415","doi-asserted-by":"crossref","DOI":"10.3390\/cells13121061","article-title":"Down-regulation of AKT proteins slows the growth of mutant-KRAS pancreatic tumors","volume":"13","author":"Chen","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2025.108985_bb0420","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17091554","article-title":"Mechanistic roles of transcriptional cyclin-dependent kinases in oncogenesis: implications for cancer therapy","volume":"17","author":"Alrouji","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2025.108985_bb0425","doi-asserted-by":"crossref","first-page":"8667","DOI":"10.1021\/acs.jmedchem.6b00150","article-title":"Cyclin dependent kinase 9 inhibitors for cancer therapy","volume":"59","author":"Sonawane","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108985_bb0430","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3390\/cancers7010179","article-title":"Targeting cyclin-dependent kinases in human cancers: from small molecules to peptide inhibitors","volume":"7","author":"Peyressatre","year":"2015","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2025.108985_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128061","article-title":"Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax","volume":"43","author":"King","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108985_bb0440","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1158\/0008-5472.CAN-09-1107","article-title":"Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling","volume":"70","author":"Feldmann","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108985_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118085","article-title":"Novel dual-targeting PROTAC degraders of GSK-3beta and CDK5: a promising approach for pancreatic cancer treatment","volume":"120","author":"Neerasa","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108985_bb0450","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.108985_bb0455","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/bjc.2014.215","article-title":"Oncogenic KRAS signalling in pancreatic cancer","volume":"111","author":"Eser","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2025.108985_bb0460","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2025.108985_bb0465","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1021\/acscentsci.0c00411","article-title":"Targeted degradation of oncogenic KRAS(G12C) by VHL-recruiting PROTACs","volume":"6","author":"Bond","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.bioorg.2025.108985_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114088","article-title":"Efficient targeted oncogenic KRAS(G12C) degradation via first reversible-covalent PROTAC","volume":"230","author":"Yang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108985_bb0475","doi-asserted-by":"crossref","first-page":"10238","DOI":"10.1021\/acs.jmedchem.5c00428","article-title":"Discovery and characterization of RP03707: a highly potent and selective KRAS(G12D) PROTAC","volume":"68","author":"Ji","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108985_bb0480","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.2174\/0929867324666170206142658","article-title":"Targeting the Akt\/PI3K signaling pathway as a potential therapeutic strategy for the treatment of pancreatic cancer","volume":"24","author":"Ebrahimi","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108985_bb0485","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231710132","article-title":"Targeting PI3K\/AKT\/mTOR signaling pathway in pancreatic cancer: from molecular to clinical aspects","volume":"23","author":"Stanciu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.108985_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103749","article-title":"Prospects of targeting PI3K\/AKT\/mTOR pathway in pancreatic cancer","volume":"176","author":"Mortazavi","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bioorg.2025.108985_bb0495","doi-asserted-by":"crossref","first-page":"12800","DOI":"10.1021\/acs.jmedchem.5c00679","article-title":"Discovery and optimization of potent PROTAC degraders of phosphoinositide 3-kinase with significant in vivo anticancer efficacy","volume":"68","author":"Peng","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108985_bb0500","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1056\/NEJMra1112635","article-title":"Targeting epigenetic readers in cancer","volume":"367","author":"Dawson","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2025.108985_bb0505","doi-asserted-by":"crossref","first-page":"16168","DOI":"10.1021\/acs.jmedchem.3c01521","article-title":"Discovery of potent and selective WDR5 proteolysis targeting chimeras as potential therapeutics for pancreatic cancer","volume":"66","author":"Yu","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108985_bb0510","doi-asserted-by":"crossref","DOI":"10.3390\/jcm7020021","article-title":"Moonlighting with WDR5: a cellular multitasker","volume":"7","author":"Guarnaccia","year":"2018","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bioorg.2025.108985_bb0515","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/nrd.2017.179","article-title":"WD40 repeat domain proteins: a novel target class?","volume":"16","author":"Schapira","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2025.108985_bb0520","doi-asserted-by":"crossref","DOI":"10.1242\/dev.159889","article-title":"WDR5 regulates left-right patterning via chromatin-dependent and -independent functions","volume":"145","author":"Kulkarni","year":"2018","journal-title":"Development"},{"key":"10.1016\/j.bioorg.2025.108985_bb0525","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.celrep.2016.05.063","article-title":"In vivo functional platform targeting patient-derived xenografts identifies WDR5-Myc association as a critical determinant of pancreatic cancer","volume":"16","author":"Carugo","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.bioorg.2025.108985_bb0530","first-page":"391","article-title":"In vivo RNAi screening for pancreatic cancer drivers: PILOTing the WDR5-MYC Axis, trends","volume":"2","author":"Schneider","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.bioorg.2025.108985_bb0535","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/gutjnl-2016-312539","article-title":"Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?","volume":"66","author":"Hessmann","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.bioorg.2025.108985_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117875","article-title":"Synthesis, SAR, and application of JQ1 analogs as PROTACs for cancer therapy","volume":"112","author":"De","year":"2024","journal-title":"Bioorg. Med. Chem."},{"issue":"13","key":"10.1016\/j.bioorg.2025.108985_bb0545","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202500133","article-title":"Hijacking the MDM2 E3 ligase with novel BRD4-targeting proteolysis-targeting chimeras in pancreatic cancer cells","volume":"26","author":"Ficu","year":"2025","journal-title":"ChemBioChem"},{"key":"10.1016\/j.bioorg.2025.108985_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117970","article-title":"Enhancing therapeutic efficacy in homologous recombination-proficient pancreatic cancer via the combination of PARP1-PROTAC and a BRD4 inhibitor","volume":"115","author":"Pu","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108985_bb0555","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1158\/0008-5472.CAN-24-0927","article-title":"KHSRP stabilizes m6A-modified transcripts to activate FAK signaling and promote pancreatic ductal adenocarcinoma progression","volume":"84","author":"Xu","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108985_bb0560","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.108985_bb0565","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41392-025-02176-0","article-title":"The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy","volume":"10","author":"Vogler","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2025.108985_bb0570","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/1535-7163.MCT-21-0474","article-title":"Overcoming gemcitabine resistance in pancreatic cancer using the BCL-X(L)-specific degrader DT2216","volume":"21","author":"Thummuri","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2025.108985_bb0575","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13045-022-01241-3","article-title":"BCL-X(L) PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRAS(G12C)-mutated cancers","volume":"15","author":"Khan","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2025.108985_bb0580","article-title":"Molecular imaging: unveiling metabolic abnormalities in pancreatic cancer","volume":"26","author":"Wang","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.108985_bb0585","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.semcancer.2022.09.001","article-title":"Lactate dehydrogenase and its clinical significance in pancreatic and thoracic cancers","volume":"86","author":"Comandatore","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bioorg.2025.108985_bb0590","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1021\/acs.jmedchem.2c01505","article-title":"Discovery of the first lactate dehydrogenase proteolysis targeting chimera degrader for the treatment of pancreatic cancer","volume":"66","author":"Sun","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108985_bb0595","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2024-334361","article-title":"Histone lactylation-driven feedback loop modulates cholesterol-linked immunosuppression in pancreatic cancer","author":"Yang","year":"2025","journal-title":"Gut"},{"issue":"2025","key":"10.1016\/j.bioorg.2025.108985_bb0600","article-title":"Endoplasmic reticulum stress in cancer","volume":"6","author":"Zhou","year":"2020","journal-title":"MedComm"},{"key":"10.1016\/j.bioorg.2025.108985_bb0605","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1158\/0008-5472.CAN-20-1540","article-title":"The hydroxyquinoline analogue YUM70 inhibits GRP78 to induce ER stress-mediated apoptosis in pancreatic cancer","volume":"81","author":"Samanta","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108985_bb0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e34269","article-title":"Epithelial-mesenchymal plasticity (EMP) in wound healing: exploring EMT mechanisms, regulatory network, and therapeutic opportunities","volume":"10","author":"Yao","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.bioorg.2025.108985_bb0615","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.1111\/cas.15162","article-title":"SNAIL2 contributes to tumorigenicity and chemotherapy resistance in pancreatic cancer by regulating IGFBP2","volume":"112","author":"Masuo","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bioorg.2025.108985_bb0620","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1158\/0008-5472.CAN-20-4263","article-title":"The transcription factor SLUG uncouples pancreatic cancer progression from the RAF-MEK1\/2-ERK1\/2 pathway","volume":"81","author":"Bilal","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108985_bb0625","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ccell.2019.10.002","article-title":"A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo","volume":"36","author":"Bai","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2025.108985_bb0630","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1021\/acs.jmedchem.0c01897","article-title":"Discovery of a NAPABUCASIN PROTAC as an effective degrader of the E3 ligase ZFP91","volume":"64","author":"Hanafi","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108985_bb0635","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41587-021-01173-2","article-title":"The PROTAC gold rush","volume":"40","author":"Garber","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bioorg.2025.108985_bb0640","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1021\/acsmedchemlett.0c00194","article-title":"Systematic investigation of the permeability of androgen receptor PROTACs","volume":"11","author":"Scott","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108985_bb0645","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1021\/acscentsci.6b00280","article-title":"Protein degradation by in-cell self-assembly of proteolysis targeting chimeras","volume":"2","author":"Lebraud","year":"2016","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.bioorg.2025.108985_bb0650","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/17460441.2023.2187047","article-title":"Investigating the cell permeability of proteolysis-targeting chimeras (PROTACs)","volume":"18","author":"Yokoo","year":"2023","journal-title":"Expert Opin. Drug Discovery"},{"key":"10.1016\/j.bioorg.2025.108985_bb0655","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jconrel.2020.11.032","article-title":"Enhanced protein degradation by intracellular delivery of pre-fused PROTACs using lipid-like nanoparticles","volume":"330","author":"Chen","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bioorg.2025.108985_bb0660","article-title":"The PDAC extracellular matrix: a review of the ECM protein composition, cell interaction, and therapeutic strategies","volume":"11","author":"Perez","year":"2021","journal-title":"Tumor Front. Oncol."},{"key":"10.1016\/j.bioorg.2025.108985_bb0665","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","article-title":"Pancreatic cancer stroma: an update on therapeutic targeting strategies","volume":"17","author":"Hosein","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bioorg.2025.108985_bb0670","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14153737","article-title":"Cancer associated fibroblast (CAF) regulation of PDAC parenchymal (CPC) and CSC phenotypes is modulated by ECM composition","volume":"14","author":"Cannone","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2025.108985_bb0675","article-title":"The extracellular matrix: a key accomplice of cancer stem cell migration, metastasis formation, and drug resistance in PDAC","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2025.108985_bb0680","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1021\/acsptsci.3c00304","article-title":"Polydopamine-based resveratrol-hyaluronidase nanomedicine inhibited pancreatic cancer cell invasive phenotype in hyaluronic acid enrichment tumor sphere model","volume":"7","author":"Yu","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.bioorg.2025.108985_bb0685","doi-asserted-by":"crossref","first-page":"1505255","DOI":"10.3389\/fmolb.2024.1505255","article-title":"Precision-engineered PROTACs minimize off-tissue effects in cancer therapy","volume":"11","author":"Shi","year":"2024","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.bioorg.2025.108985_bb0690","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.scib.2023.04.028","article-title":"Stimuli-activatable PROTACs for precise protein degradation and cancer therapy","volume":"68","author":"Gao","year":"2023","journal-title":"Sci. Bull. (Beijing)"},{"key":"10.1016\/j.bioorg.2025.108985_bb0695","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13236135","article-title":"Tumor microenvironment features and chemoresistance in pancreatic ductal adenocarcinoma: insights into targeting physicochemical barriers and metabolism as therapeutic approaches","volume":"13","author":"Carvalho","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2025.108985_bb0700","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202306824","article-title":"Stimuli-responsive PROTACs for controlled protein degradation","volume":"62","author":"An","year":"2023","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.bioorg.2025.108985_bb0705","doi-asserted-by":"crossref","first-page":"10072","DOI":"10.1039\/D2CC03367D","article-title":"Reactive oxygen species-responsive pre-PROTAC for tumor-specific protein degradation","volume":"58","author":"Liu","year":"2022","journal-title":"Chem. Commun. (Camb.)"},{"key":"10.1016\/j.bioorg.2025.108985_bb0710","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202300422","article-title":"Hydrogen peroxide-inducible PROTACs for targeted protein degradation in cancer cells","volume":"24","author":"Yu","year":"2023","journal-title":"ChemBioChem"},{"key":"10.1016\/j.bioorg.2025.108985_bb0715","doi-asserted-by":"crossref","first-page":"12852","DOI":"10.1039\/D1CC05715D","article-title":"Development of hypoxia-activated PROTAC exerting a more potent effect in tumor hypoxia than in normoxia","volume":"57","author":"Cheng","year":"2021","journal-title":"Chem. Commun. (Camb.)"},{"key":"10.1016\/j.bioorg.2025.108985_bb0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117237","article-title":"Design, synthesis and biological evaluation of the tumor hypoxia-activated PROTACs bearing caged CRBN E3 ligase ligands","volume":"82","author":"Cheng","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108985_bb0725","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41392-024-01983-1","article-title":"Sequential responsive nano-PROTACs for precise intracellular delivery and enhanced degradation efficacy in colorectal cancer therapy","volume":"9","author":"Yang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2025.108985_bb0730","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12943-024-02024-9","article-title":"New-generation advanced PROTACs as potential therapeutic agents in cancer therapy","volume":"23","author":"Wang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioorg.2025.108985_bb0735","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/acschembio.0c00285","article-title":"Antibody-PROTAC conjugates enable HER2-dependent targeted protein degradation of BRD4","volume":"15","author":"Maneiro","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.108985_bb0740","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15020411","article-title":"Cancer-specific delivery of proteolysis-targeting chimeras (PROTACs) and their application to cancer immunotherapy","volume":"15","author":"Moon","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioorg.2025.108985_bb0745","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.1021\/jacs.1c00451","article-title":"Cancer selective target degradation by folate-caged PROTACs","volume":"143","author":"Liu","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bioorg.2025.108985_bb0750","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.576399","article-title":"Stroma-targeting therapy in pancreatic cancer: one coin with two sides?","volume":"10","author":"Jiang","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2025.108985_bb0755","first-page":"78","article-title":"Lessons in PROTAC design from selective degradation with a promiscuous warhead, cell","volume":"25","author":"Bondeson","year":"2018","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.108985_bb0760","doi-asserted-by":"crossref","first-page":"7666","DOI":"10.1021\/acs.jcim.4c01227","article-title":"Characterizing the cooperative effect of PROTAC systems with end-point binding free energy calculation","volume":"64","author":"Xu","year":"2024","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2025.108985_bb0765","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1111\/bph.15014","article-title":"Proteolysis-targeting chimeras in drug development: a safety perspective","volume":"177","author":"Moreau","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108985_bb0770","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1023\/A:1015372322419","article-title":"Aiolos and Ikaros: regulators of lymphocyte development, homeostasis and lymphoproliferation","volume":"7","author":"Schmitt","year":"2002","journal-title":"Apoptosis"},{"key":"10.1016\/j.bioorg.2025.108985_bb0775","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1172\/JCI98164","article-title":"Dominant-negative IKZF1 mutations cause a T, B, and myeloid cell combined immunodeficiency","volume":"128","author":"Boutboul","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bioorg.2025.108985_bb0780","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188387","article-title":"Local and systemic immunosuppression in pancreatic cancer: targeting the stalwarts in tumor\u2019s arsenal","volume":"1874","author":"Mundry","year":"2020","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.bioorg.2025.108985_bb0785","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"Bekes","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2025.108985_bb0790","doi-asserted-by":"crossref","first-page":"eaay5154","DOI":"10.1126\/sciadv.aay5154","article-title":"Light-induced control of protein destruction by opto-PROTAC","volume":"6","author":"Liu","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bioorg.2025.108985_bb0795","doi-asserted-by":"crossref","first-page":"eaay5064","DOI":"10.1126\/sciadv.aay5064","article-title":"PHOTACs enable optical control of protein degradation","volume":"6","author":"Reynders","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bioorg.2025.108985_bb0800","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1021\/jacs.9b12718","article-title":"Optical control of small molecule-induced protein degradation","volume":"142","author":"Naro","year":"2020","journal-title":"J. Am. Chem. Soc."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682500865X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682500865X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T20:29:11Z","timestamp":1760560151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004520682500865X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":160,"alternative-id":["S004520682500865X"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108985","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted protein degradation in pancreatic cancer: advances and challenges of PROTAC-based therapeutics","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108985","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108985"}}